A Looming Crisis: HIV Drug Access Under Threat
In a worrying development, constrained state budgets are forcing a reevaluation of HIV care and prevention programs, with a particular focus on the Ryan White HIV/AIDS Program. This program, a vital safety net for those living with HIV, is funded through a combination of federal and state appropriations, but the funding often falls short of the actual need and cost of services.
The Ryan White Program's largest component provides grants to states, including funding for their AIDS Drug Assistance Programs (ADAPs). ADAPs have historically faced challenges, resorting to waiting lists and other cost-containment measures when demand outstripped resources. While waiting lists were common in the early 2000s, they were last cleared in 2013 with emergency federal funding. However, several states, under budget pressure, are now considering reintroducing these measures, including waiting lists.
But here's where it gets controversial: these changes could result in people with HIV losing access to essential care and treatment. This not only worsens health outcomes, leading to increased morbidity and mortality, but also contributes to new HIV infections. Studies show that four in ten new HIV transmissions are linked to individuals who are aware of their status but not receiving proper care.
State Responses: Limiting Enrollment and Services
Florida, for instance, has recently announced drastic changes to its ADAP. The state plans to significantly reduce income eligibility, dropping it from 400% of the federal poverty level to 130% FPL for individuals. This equates to a substantial decrease in maximum annual income from $63,840 to $20,748. Additionally, Florida intends to remove Biktarvy, the most widely prescribed antiretroviral medication, from its formulary, and roll back insurance assistance programs, which help individuals cover both HIV-related and other healthcare needs.
These changes have faced strong opposition from advocates, patients, and providers, and the state has even been sued for proceeding without formal rule-making. However, Florida is not alone. New data shows that 23 states, including Washington, D.C., are implementing or considering ADAP cost-containment measures. Eighteen ADAPs have already made or are making changes, and five more states are considering similar actions.
For example, Pennsylvania, Kansas, Delaware, and Rhode Island have also reduced income eligibility for their programs. Other states are exploring measures like reducing formularies, cutting funding for medical and support services, implementing annual client spending caps, and restricting or ending health insurance assistance.
Budget Pressures and Their Causes
Multiple factors are contributing to the budget pressures on ADAPs. Since 1996, Congress has allocated a set amount of funding for ADAPs, but this funding has not kept pace with inflation. In fact, inflation-adjusted appropriations have declined by 31% since 2005. This decline is largely due to over a decade of flat funding in nominal dollars.
According to a NASTAD report, ADAPs cite growing client enrollment, rising drug costs, and increasing insurance costs as their top budget concerns. The number of ADAP clients has increased significantly, with a 56% rise from 2007 to 2024. Additionally, the national HIV treatment guidelines now recommend treatment at diagnosis, further increasing the demand for services.
The cost of HIV drugs is also a significant factor. A recent analysis found that the average wholesale price of recommended initial antiretroviral regimes increased from $24,970 to $35,160 in 2012 to $36,080 to $48,000 in 2018, and costs have continued to rise. ADAPs, while benefiting from price discounts through the 340B drug pricing program and manufacturer rebates, are still affected by these increasing prices.
Furthermore, the expiration of enhanced premium tax credits under the Affordable Care Act has led to a substantial increase in insurance premium costs. These tax credits helped make marketplace plans more affordable for people with low to moderate incomes, but their expiration has resulted in a significant financial burden for ADAPs and their clients.
Looking Ahead: A Growing Challenge
ADAPs have tried to address budget shortfalls by leveraging additional state funds, drug rebates, and emergency funding, but these efforts have not been sufficient. As a result, many states are implementing cost-containment measures, and these pressures may lead to further measures in the future. This could leave an increasing number of people with HIV ineligible for safety-net services, especially if states further reduce income eligibility limits or reintroduce waiting lists.
The expiration of enhanced tax credits exacerbates these challenges, increasing costs for programs and leaving those ineligible for ADAPs with limited affordable alternatives. Limiting access to Ryan White services will impact the ability of people with HIV to stay engaged in treatment, which is a critical component of national efforts to address the HIV epidemic.
This situation raises important questions: How can we ensure that those living with HIV receive the care and treatment they need? What steps can be taken to alleviate the financial burden on ADAPs and their clients? The answers to these questions are crucial in our ongoing battle against the HIV epidemic.
